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Eotaxin-1/CCL11 is a chemokine originally implicated in the selective recruitment of
eosinophils into inflammatory sites during allergic reactions, being thoroughly investigated
in asthma, allergic rhinitis, and other eosinophil-related conditions. Eotaxin-1/CCL11 is
also involved with a skewed immune response toward a type-2 (Th2) profile. In addition
to its role in immune response, recent studies have shown that eotaxin-1/CCL11 is
associated with aging, neurogenesis and neurodegeneration, being able to influence
neural progenitor cells, and microglia. Increased circulating levels of eotaxin-1/CCL11
have been described in major psychiatric disorders (schizophrenia, bipolar disorder,
major depression), sometimes correlating with the severity of psychopathological and
cognitive parameters. As similar findings have been reported in neurodegenerative
conditions such as Alzheimer’s disease, it has been hypothesized that mechanisms
involving eotaxin-1/CCL11 signaling may underlie the “accelerated aging” profile
commonly linked to psychiatric disorders. Future studies must determine whether
eotaxin-1/CCL11 can be regarded as a prognostic biomarker and/or as therapeutic
target for resistant/progressive cases.
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INTRODUCTION
There is a robust body of evidence showing altered circulating levels of immune cells andmolecules
in patients with psychiatric disorders, usually indicating a low-grade systemic inflammation (1, 2).
Immune markers have been regarded as potential biomarkers in Psychiatry due to the role played
by the immune system in the physiopathology of major psychiatric disorders and the relatively easy
access to them (3).
Chemokines—the contraction of “chemotactic” and “cytokine”—constitute a large family of low
molecular-weight cytokines whose main action is the recruitment of leukocytes into inflammatory
sites (4, 5). Leukocyte recruitment is a highly regulated process, and chemokines are implicated
in integrin-mediated adhesion of rolling leukocytes on endothelial cells among other effects.
Chemokines are divided into four families based on the relative position of their cysteine residues
and their function, being the CCL and CXCL the two largest families. They act by binding to seven-
transmembrane G protein-coupled receptors, hence, activating signaling cascades that lead to shape
rearrangement and cell movement (4, 5).
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Due to the interest in investigating immune biomarkers
and their role in the physiopathology of psychiatric disorders,
chemokines have been explored in different conditions, including
major depression, bipolar disorder, and schizophrenia (6, 7). Our
group was one of the very first to systematically evaluate the
potential of chemokines as biomarkers of psychiatric disorders.
In 2008, we reported increased serum levels of eotaxin-1/CCL11,
but not other chemokines, in patients with chronic schizophrenia
compared to age and gender-matched controls (8). Subsequent
studies extended this finding to propose a role for eotaxin-
1/CCL11 as an aging-related biomarker in psychiatry.
In this non-systematic mini-review we revisit the actions
originally and currently ascribed to eotaxin-1/CCL11,
highlighting the emerging role of eotaxin-1/CCL11 in psychiatric
disorders, mainly schizophrenia and mood disorders.
EOTAXIN-1/CCL11: FROM EOSINOPHIL
RECRUITMENT TO A BROADER
PATHOPHYSIOLOGICAL ROLE
In 1994, studying a model of allergic inflammation, the group
of Prof. Timothy Williams at the National Heart and Lung
Institute, London, described a new protein capable of selectively
recruiting eosinophils, but not neutrophils, into inflammatory
sites. The protein named “eotaxin” was a potent stimulator of
both rodent and human eosinophils in vitro (9, 10). Subsequent
studies confirmed the role of “eotaxin” as a potent eosinophil
chemoattractant cytokine, also describing its main receptor,
the CC chemokine receptor 3 (CCR3) (11–13). “Eotaxin” was
renamed eotaxin-1 after eotaxin-2 and eotaxin-3 were identified,
and later CCL11 (14). Eotaxin-1/CCL11 can also bind to the
CCR2 and CCR4 receptors, but its selectivity to CCR3 is much
higher than to the other receptors (15).
Eosinophils have been implicated in a broad range of
conditions, notably allergic (asthma, rhinitis, and atopic
dermatitis) and inflammatory diseases characterized by
eosinophil accumulation in tissues (eosinophilic esophagitis,
gastroenteritis, and pneumonia), and helminthic diseases (for
example, schistosomiasis). Due to the pathological role of
eosinophils in asthma and atopic dermatitis, the first studies
evaluated the cellular sources of eotaxin-1/CCL11 in the
lung and the skin, reporting that epithelial cells, fibroblasts,
smooth muscle cells can produce it. Subsequently, other
sources of eotaxin-1/CCL11 were reported, including astrocytes,
chondrocytes, and tissue resident macrophages. In the central
nervous system (CNS), choroid plexus epithelial cells, pericytes,
astrocytes, and microglia seem to produce eotaxin-1/CCL11
under inflammatory stimuli (16) (Figure 1).
Once binding to CCR3 receptors expressed on the cell surface
of eosinophils, eotaxin-1/CCL11 activates a series of intracellular
signaling cascades, leading to eosinophil recruitment to
inflammatory sites. Eosinophils are source of cytotoxic granular
proteins and growth factors responsible, respectively, for tissue
damaging and remodeling implicated in the physiopathology of
several diseases such as asthma. Therefore, the selective blockade
of the CCR3-eotaxin-1/CCL11 axis could impair eosinophil
recruitment, representing an attractive target for the treatment of
asthma, allergic rhinitis, and other eosinophil-related conditions
(17). Indeed, there have been early phase clinical trials with
CCR3 antagonists for asthma and, more recently, a therapeutic
antibody against eotaxin-1/CCL11 (Bertilimumab) for allergic
rhinitis (10, 18). From a clinical perspective, eotaxin-1/CCL11
has also been evaluated as a biomarker of human diseases (19). A
systematic review of the literature involving 30 studies showed
that blood and sputum eotaxin-1/CCL11 concentrations were
consistently elevated in patients with asthma, being negatively
correlated with lung function, indicating the potential use
of eotaxin-1/CCL11 as a biomarker for the diagnosis and
assessment of asthma severity and control (20).
Besides eosinophils, the chemokine receptor CCR3 is
expressed on basophils, mast cells and Th2 lymphocytes, the
latter involved with the production of the so-called Th2 cytokines
(interleukins, IL; IL-4, IL-5, IL-13) (Figure 1). Accordingly,
eotaxin-1/CCL11 has been implicated in skewing the immune
response toward a type-2 (Th2) response (21).
In addition to immunomodulation, other effects of eotaxin-
1/CCL11 have been described. For the current discussion, it
is worth emphasizing its effects on the CNS, and mentioning
that eotaxin-1/CCL11 can cross the unaltered blood-brain
barrier (22). Krathwohl and Kaiser (23) showed that eotaxin-
1/CCL11 reversibly inhibits neural progenitor cell proliferation
in vitro in isolated cells, neurospheres, and in hippocampal slice
cultures without affecting their ability to form both neurons
and astrocytes (23). In an elegant study using parabiosis,
(24) showed that plasma of aging mice or eotaxin-1/CCL11
administration to young mice decreased adult neurogenesis
and impaired memory and learning, proposing a major role
for this chemokine in the age-related decline of hippocampal
function (24). Later, it was demonstrated that while there
was no direct effect of eotaxin-1/CCL11 on neurons, this
chemokine was able to promote microglia migration and
activation with subsequent production of reactive oxygen species,
potentiating glutamate-induced neuronal death (25). In this
same direction, our group described elevated levels of eotaxin-
1/CCL11 in the hippocampus along with impaired neurogenesis
and cognitive/memory impairment in a mouse model of cerebral
malaria (26). Altogether, these findings suggest a link between




To the best of our knowledge, the first studies assessing eotaxin-
1/CCL11 in psychiatric disorders were published in 2008 (8, 27)
(Table 1).
Simon et al. (27) simultaneously assessed the serum levels
of 22 cytokines/chemokines, including eotaxin-1/CCL11, in
49 patients with major depression and 49 matched controls,
reporting increased levels of the molecule in a context of
“generalized chronic inflammatory state” (27). Later we found
similar results in an independent cohort of patients with major
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FIGURE 1 | Schematic effects of eotaxin-1/CCL11 in adult subjects. The main sources, targets, and effects of the chemokine eotaxin-1/CCL11 are shown both in
peripheral tissues and CNS. Note that eotaxin-1/CCL11 is capable of crossing the BBB and influencing CNS cells. BBB, blood-brain barrier; CNS, central nervous
system; ROS, reactive oxygen species.
depression, indicating that increased serum levels of eotaxin-
1/CCL11 were particularly associated with suicidal ideation
(28). Nevertheless, a recent systematic-review and meta-analysis
of studies evaluating eotaxin-1/CCL11 in depression (not
necessarily major depression) including 454 participants (230
cases vs. 224 controls) failed to identify significant difference
between CCL11 measurements in depressed and control subjects
(29). The fact that this meta-analysis also included studies
with subjects presenting with medical comorbidities (including
inflammatory-related conditions) and possibly milder forms
of depression may explain the discordance with the first
reports.
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TABLE 1 | Main findings regarding eotaxin-1/CCL11 levels in major psychiatric
disorders.
Psychiatric disorder Findings
Schizophrenia Increased blood levels;
Negative correlation with telomere length and
gray matter volume;
Negative correlation with cognitive measures;
Positive correlation with negative symptoms.
Bipolar disorder Increased blood levels; Association with illness
stage.
Major depression Increased blood levels;
Association with suicidal ideation.
Dysthymia Increased blood levels.
Obsessive-compulsive disorder Blood levels similar to controls.
Autism spectrum disorder Increased blood levels.
Substance abuse disorder In heroin dependent subjects, increased blood
levels and association with age.
In alcohol dependent subjects, decreased
blood levels, especially in women and with
comorbid psychiatric disorders.
Teixeira et al. (8) evaluated the serum levels of six chemokines
(CCL2, CCL3, CCL11, CXCL8, CXCL9, CXCL10) in 40 patients
with chronic schizophrenia and 20 controls. Only the levels
of eotaxin-1/CCL11 were increased in the patients compared
to controls, but no association was found between chemokine
levels and clinical parameters such as severity of positive and
negative symptoms, and involuntary movements (8). Soon after,
we evaluated the serum levels of a set of chemokines (CCL2,
CCL3, CCL11, CCL24, CXCL8, CXCL9, CXCL10) in 30 euthymic
patients with bipolar disorder and 30 matched controls (30).
Patients with bipolar disorder showed increased levels of IP-
10/CXCL10, lower levels of eotaxin-2/CCL24 and similar levels
of the other chemokines compared to controls. Taking into
account that IP-10/CXCL10 is associated with a Th1 response,
and eotaxin-2/CCL24 (as eotaxin-1/CCL11) is related to a
Th2 response, this result suggested an imbalance of Th1/Th2
cytokines toward a Th1 profile in bipolar disorder (30). Based
on the chemokine studies, at this point we were very excited
with the hypothesis that schizophrenia would be associated
with a preferential activation of Th2 lymphocytes as previously
proposed by Muller et al. (31), while bipolar disorder with the
activation of Th1 lymphocytes.
Nevertheless, subsequent studies failed to confirm immune
response polarization in schizophrenia or bipolar disorder (1).
Studying the plasma levels of six chemokines (CCL2, CCL3,
CCL11, CCL24, CXCL8, and CXCL10) in an independent
sample composed of 70 bipolar disorder type I patients (35
in euthymia and 35 in mania) and 50 matched controls, we
found increased levels of IP-10/CXCL10 and eotaxin-1/CCL11
in patients regardless of the mood phase (32). Magalhaes
et al. (33) also reported increased levels of eotaxin-1/CCL11 in
patients with bipolar disorder recruited from the community
(33). Actually, there are similarities in the pattern of cytokine
changes in schizophrenia and bipolar disorder during acute and
chronic phases of the respective illness, possibly indicating shared
pathophysiological pathways leading to immune dysfunction
(34). Different results were obtained when evaluating patients
with obsessive-compulsive disorder.
More recently, we showed that late-stage patients with
bipolar disorder, defined by a clinical staging model taking
into consideration the number of previous mood episodes,
comorbidities, and cognitive and social functioning, tended to
express higher serum levels of eotaxin-1/CCL11 than early-stage
patients and controls (35). This study supported the findings
of altered levels of eotaxin-1/CCL11 in bipolar disorder, and
indicated an increase in the circulating levels of this chemokine
with progressive clinical deterioration observed in this condition.
Moreover, taking into account the evidence implicating eotaxin-
1/CCL11 in the age-related decline of hippocampal function,
including memory and learning impairment (24, 25), it
corroborates the hypothesis of “accelerated aging” in bipolar
disorder (36). We observed similar findings in schizophrenia
(37) as patients with chronic illness (>20 years of diagnosis) had
higher circulating levels of eotaxin-1/CCL11 than age-matched
controls, while patients with early illness (<5 years of diagnosis)
did not differ from their age-matched controls.
In a recent study comprising 48 patients with schizophrenia
and 64 controls, we had the chance to reiterate the hypothesis
of “accelerated aging” in this major psychiatric condition (38).
In comparison with controls, patients had decreased telomere
length (a biological marker of aging) and gray matter volume (a
neuroimaging marker of aging/degeneration), increased eotaxin-
1/CCL11 levels, and worse memory performance as assessed
by the Hopkins Verbal Learning Test. More importantly,
shorter telomere length was related to increased levels of
eotaxin-1/CCL11, and both biomarkers were related to reduced
gray matter volume, all of which were related to worse
memory functioning. Further supporting a role for eotaxin-
1/CCL11 in human cognition, (39) reported increased levels
of this chemokine in patients with schizophrenia compared
to controls, and a negative correlation with working memory
(Visual Working Memory Test) and a positive correlation
with cognitive flexibility (Plus-Minus Task) (39). Noto et al.
(40) also reported a positive correlation between the severity
of negative symptoms (i.e., apathy, blunted affect, poverty of
speech, social withdrawal) and eotaxin-1/CCL11 levels (40).
An independent group corroborated these results, reporting
positive correlation between eotaxin-1/CCL11 levels with age,
duration of schizophrenia, and severity of negative symptoms
(41). Although correlational, these findings suggest that eotaxin-
1/CCL11 may influence the function of different neural
circuits, including dorsolateral, and ventromedial fronto-striatal
circuits.
In line with the indirect findings implicating eotaxin-1/CCL11
in “accelerated aging” in bipolar disorder and schizophrenia,
elevated plasma levels of eotaxin-1/CCL11 have been observed in
neurodegenerative diseases, mainly Alzheimer’s disease (42, 43).
It remains to be established whether these levels correlate with
the rate of disease/neurodegeneration progression.
Finally, it is worth mentioning that altered levels of eotaxin-
1/CCL11 has been associated with children and adolescent
psychopathology, including autism spectrum disorder (44, 45),
and other psychiatric conditions, including dysthymia (46),
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obsessive-compulsive disorder (47), and substance use disorders
(48, 49).
CONCLUDING REMARKS
Eotaxin-1/CCL11 has been associated with major psychiatric
disorders. This finding undermines its role as a diagnostic
marker, but suggests that this chemokine may be involved in
shared pathophysiological mechanisms among them, especially
those implicated in “accelerated aging.” In this regard, eotaxin-
1/CCL11 seems very promising as it has been associated
with markers of aging and degeneration; also correlating with
cognitive measures. There are several opportunities here such
as: (i) longitudinal studies with careful psychopathological
and cognitive phenotyping aiming to determine its prognostic
value; (ii) neuroimaging studies to evaluate its association with
neurodegenerative changes (e.g. PET analysis of beta-amyloid
and tau burden). For example, eotaxin-1/CCL11 has been used
as a biomarker in clinical trials in asthma (50, 51).
In sum, although preliminary, there is evidence supporting
that eotaxin-1/CCL11 may exert physiological and pathological
effects in the CNS. If confirmed these pathological effects, it is
tempting to propose strategies against eotaxin-1/CCL11 or its
CCR3 receptor for the treatment of severe, progressing, and/or
refractory cases of major psychiatric disorders. There have been
clinical trials with CCR3 antagonists and anti-eotaxin-1/CCL11
neutralizing antibodies in inflammatory human diseases with
encouraging results.
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